NewEdge Wealth LLC purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 511 shares of the company’s stock, valued at approximately $256,000.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Moneta Group Investment Advisors LLC lifted its holdings in IDEXX Laboratories by 121,647.2% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock valued at $3,038,192,000 after acquiring an additional 7,441,162 shares during the last quarter. Norges Bank acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $336,416,000. Alliancebernstein L.P. grew its stake in shares of IDEXX Laboratories by 11.5% in the fourth quarter. Alliancebernstein L.P. now owns 3,240,710 shares of the company’s stock worth $1,322,080,000 after acquiring an additional 334,020 shares during the last quarter. Morgan Stanley grew its position in IDEXX Laboratories by 36.0% in the 4th quarter. Morgan Stanley now owns 986,232 shares of the company’s stock worth $402,344,000 after purchasing an additional 260,926 shares during the last quarter. Finally, Winslow Capital Management LLC lifted its position in IDEXX Laboratories by 31.4% in the fourth quarter. Winslow Capital Management LLC now owns 873,084 shares of the company’s stock worth $356,183,000 after purchasing an additional 208,387 shares during the period. 86.53% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other IDEXX Laboratories news, EVP Michael Lane sold 16,027 shares of the stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $510.00, for a total transaction of $8,173,770.00. Following the transaction, the executive vice president now owns 4,034 shares in the company, valued at approximately $2,057,340. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Jonathan W. Ayers sold 10,000 shares of the company’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $489.23, for a total transaction of $4,892,300.00. Following the completion of the sale, the director now owns 137,039 shares in the company, valued at $67,043,589.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Lane sold 16,027 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $510.00, for a total transaction of $8,173,770.00. Following the transaction, the executive vice president now directly owns 4,034 shares in the company, valued at approximately $2,057,340. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Get Our Latest Analysis on IDEXX Laboratories
IDEXX Laboratories Stock Performance
Shares of IDXX opened at $505.51 on Monday. The company has a current ratio of 1.33, a quick ratio of 0.89 and a debt-to-equity ratio of 0.64. IDEXX Laboratories, Inc. has a 12 month low of $317.06 and a 12 month high of $564.73. The firm has a fifty day simple moving average of $505.90 and a 200 day simple moving average of $490.50. The stock has a market capitalization of $41.96 billion, a price-to-earnings ratio of 53.66, a PEG ratio of 2.93 and a beta of 1.19.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- How to Invest and Trade Chinese Stocks
- MarketBeat Week in Review – 8/7 – 8/11
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Retailers To Watch Closely Next Week
- 5 Top Rated Dividend Stocks to Consider
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
